A group from Mayo Clinic compared 35 patients who received G-CSF after CAR T to 35 patients who did not—with no signal of increased severity of CRS or ICANS, and shorter duration of neutropenia with post-CAR T G-CSF [27]. This evidence concerns the gene CSF3 and neutropenia.